An assessment of the joint associations of aspirin and statin use with C-reactive protein concentration.

Academic Article

Abstract

  • BACKGROUND: The use of aspirin alone and statins alone has been shown to reduce markers of inflammation, including C-reactive protein (CRP); however, their combination has been poorly studied. METHODS: In a cross-sectional analysis of black and white adults > or =45 years old from the REGARDS cohort, the associations of aspirin and statin use with CRP were examined. Individuals requiring nonsteroidal anti-inflammatory drug therapy or those taking aspirin for reasons other than cardioprotection were excluded from analysis. Participants were classified into 1 of 4 groups: aspirin only (n = 3,673), statin only (n = 1,898), both agents (n = 3,008), or neither agent (n = 7,718). RESULTS: Estimated mean CRP was 2.78 mg/L for subjects taking neither drug, 2.73 mg/L with aspirin only, 2.29 mg/L with statins only, and 2.03 mg/L for subjects taking both agents. The combined use of both agents was associated with an apparent synergistically lower CRP; the mean CRP level among these combined users was 0.21 mg/L lower than that anticipated from additive association related to aspirin and statins alone (P for interaction = .01). Associations were larger among participants reporting a history of cardiovascular disease. In addition, among statin users, the use of aspirin for >5 years compared with < or =5 years was associated with apparent significantly lower CRP concentrations (P = .01). CONCLUSIONS: The combined use of aspirin and statins was associated with a synergistically lower CRP concentration, especially among participants taking aspirin for >5 years. Given the limitations of this study and the modest associations, randomized controlled trial evidence is needed to confirm the findings.
  • Authors

    Published In

    Keywords

  • Aged, Aspirin, C-Reactive Protein, Cardiovascular Diseases, Cross-Sectional Studies, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Inflammation Mediators, Male, Middle Aged, Probability, Prognosis, Reference Values, Risk Factors, Sensitivity and Specificity
  • Digital Object Identifier (doi)

    Author List

  • Fisher M; Cushman M; Knappertz V; Howard G
  • Start Page

  • 106
  • End Page

  • 111
  • Volume

  • 156
  • Issue

  • 1